S-8660
S-8660 is an orally active, selective inhibitor of dihydroorotate dehydrogenase (DHODH). As an antiproliferative prodrug and an analog of Brequinar (HY-108325), S-8660 exhibits immunosuppressive activity. Its effect on prolonging cardiac allograft survival is enhanced when used in combination with Cyclosporin A (HY-B0579). S-8660 can be used in studies of cardiac transplant rejection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 96201-52-4
- 화학식: C23H16ClNO2
- 분자량:373.83
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
S-8660 selectively inhibits mitochondrial dihydroorotate dehydrogenase, disrupting de novo pyrimidine synthesis in a cell-free biochemical system[1].
S-8660 suppresses human mixed-lymphocyte responses in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ACI (RT1a) donors; Lewis (RT11) recipients[1]
-
Dosage:5 mg/kg; 20 mg/kg
-
Administration:p.o.; once daily; starting 2 days pre-transplant for up to 30 days post-transplant
-
Result:Extended cardiac allograft survival in a dose-dependent manner.
Achieved a median graft survival time of 32 days with the tapered dose regimen, compared to control median survival of 7 days.
Chemical Information
-
CAS No. 96201-52-4
-
분자량 373.83
-
화학식 C23H16ClNO2
-
SMILES
O=C(O)C1=C(C(C2=CC=C(C=C2)C3=CC=CC=C3)=NC4=CC=CC(Cl)=C14)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- S-8660
- 96201-52-4
- S8660
- S 8660
- Dihydroorotate Dehydrogenase
- delayed-type hypersensitivity
- antiproliferative prodrug
- immunosuppressive activity
- cardiac allograft rejection
- dihydroorotate dehydrogenase
- cardiac allograft survival
- de novo pyrimidine synthesis
- rats
- cyclosporine
- human mixed-lymphocyte responses
- Inhibitor
- inhibitor
- inhibit